



Atty. Dkt. No. 355491-1253

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Christopher D. ROBERTS et al.  
Title: NUCLEOSIDE DERIVATIVES  
FOR TREATING HEPATITIS C  
VIRUS INFECTION  
Appl. No.: 10/821,638  
Filing Date: 08 April 2004  
Examiner: Lawrence E. Crane  
Art Unit: 1623  
Confirmation Number: 9014

<b>CERTIFICATE OF EXPRESS MAILING</b>	
I hereby certify that this correspondence is being deposited with the United States Postal Service's "Express Mail Post Office To Addressee" service under 37 C.F.R. § 1.10 on the date indicated below and is addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
EV 643729380 US (Express Mail Label Number)	05 July 2006 (Date of Deposit)
SALTO, Susana (Printed Name)	
<i>S. Salto</i> (Signature)	

**RESPONSE TO STATEMENTS FOR REASONS FOR ALLOWANCE**

Mail Stop Communication  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This communication is responsive to the Notice of Allowability dated April 7, 2006, concerning the above-referenced patent application. In the Statement for Reasons for Allowance, the Examiner stated that “[t]he reference submitted by applicant has been reviewed (Biota '757, PTO-1449 ref B6) and while it prospectively discloses some of the compounds herein, the exemplifications beginning at page 78 fail to enable any compounds wherein the C-7 position of a pyrrolo[2,3-d]pyrimidine nucleoside analogue is substituted by anything but hydrogen, a generic class of compounds not claimed herein.”

For the sake of completion, Applicants note that Biota '757 does not disclose any of the compounds in the allowed claims. In the disclosed genera of compounds in Biota '757, there are many combinations of substituents such that the possible number of compounds is enormous.

Moreover, it is only by hindsight selection of appropriate substituents that compounds resembling those of the claimed can be constructed. In this regard, even in cases where a genus contains a small number of species, M.P.E.P. 2144.08 states that “[s]ome motivation is to select the claimed species or subgenus must be taught by the prior art.” Biota '757 does not provide such motivation. Accordingly, the compounds in Biota '757 do not suggest the claimed invention nor prospectively disclose some of the compounds in the allowed claims.

Respectfully submitted,

Date 7-5-06

By Gerald F. Swiss

Gerald F. Swiss  
Attorney for Applicant  
Registration No. 30,113

FOLEY & LARDNER LLP  
Customer Number: 38706  
Telephone: (650) 251-1103  
Facsimile: (650) 856-3710